<DOC>
	<DOCNO>NCT01916785</DOCNO>
	<brief_summary>This protocol multicentric interventional phase II study French CML Intergroup ( FILMC ) . The core protocol explore efficacy safety optimization strategy consist modulation dasatinib daily dose accord result repeat plasmatic level dasatinib . The objective strategy improve overall result treatment early CP-CML order avoid development resistance BCR-ABL tyrosine kinase mutation . The study conduct select FILMC Canadian center . The study sponsor Hôpitaux de Versailles support Bristol-Myers Squibb . The dasatinib treatment provide Bristol-Myers Squibb marketing authorization grant indication .</brief_summary>
	<brief_title>OPTIM DASATINIB ( Optimized Tyrosine Kinase Inhibitors Monotherapy )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year 2 . ECOG Performance Status score 02 3 . Philadelphia chromosome positive newly diagnose ( ≤ 3 month ) CPCML 4. patient previously treat except hydroxyurea imatinib ( le 4 week imatinib ) 5 . Signed write inform consent 6 . Adequate hepatic function define : total bilirubin ≤ 2.0 time institutional ULN ; ALT AST ≤ 2.5 time institutional upper limit normal ( ULN ) . 7 . Adequate renal function define serum creatinine ≤ 3 time institutional ULN . 8 . Women childbearing potential ( WOCBP ) must use adequate method contraception . 1 . Patients BCRABL positive , Philadelphia negative CML 2 . Patient previously treat tyrosine kinase inhibitor ( TKI ) except imatinib le 4 week . 3 . Pregnancy 4 . Active malignancy 5 . Uncontrolled significant cardiovascular disease 6 . Patients QTc &gt; 450 m 7 . Significant bleed disorder unrelated CML 8 . Concurrent severe disease exclude administration therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>